User menu

RELEVANCE : A phase 3 randomised study comparing efficacy and safety of rituximab plus lenalidomide versus rituximab plus chemotherapy in first-line patients with follicular lymphomat.

Bibliographic reference André, Marc. RELEVANCE : A phase 3 randomised study comparing efficacy and safety of rituximab plus lenalidomide versus rituximab plus chemotherapy in first-line patients with follicular lymphomat. . In: Belgian Journal of Hematology, Vol. 4, no.1, p. 36-38 (2013)
Permanent URL http://hdl.handle.net/2078.1/179441